Earnings per Share

12 Months Ended

Dec. 31, 2024


Note 15:			Earnings per Share

Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:


	For the Years Ended December 31,
(In millions)	2024		2023		2022
Numerator:
Net income attributable to Biogen Inc.	$	1,632.2	$	1,161.1	$	3,046.9
Denominator:
Weighted-average number of common shares outstanding	145.6		144.7		145.3
Effect of dilutive securities:

Time-vested restricted stock units	0.3		0.7		0.5
Market stock units	—		—		0.1
Performance stock units settled in stock	—		0.2		0.1
Dilutive potential common shares	0.3		0.9		0.7
Shares used in calculating diluted earnings per share	145.9		145.6		146.0

Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.

Earnings per share for the year ended December 31, 2022, reflects the repurchase of approximately 3.6 million shares of our common stock, respectively, under our 2020 Share Repurchase Program. There were no share repurchases of our common stock during the years ended December 31, 2024 and 2023. For additional information on our 2020 Share Repurchase Program, please read Note 14, Equity, to these consolidated financial statements.